三例下颌骨弥漫性大B细胞淋巴瘤采用放疗和化疗治疗。
Three cases of diffuse large B-cell lymphoma of the mandible treated with radiotherapy and chemotherapy.
作者信息
Someya Masanori, Sakata Koh-Ichi, Nagakura Hisayasu, Itou Katsuya, Nakata Kensei, Oouchi Atsushi, Satoh Masaaki, Hareyama Masato
机构信息
Department of Radiology, Sapporo Medical University, School of Medicine, Sapporo, Hokakaido, Japan.
出版信息
Radiat Med. 2005 Jun;23(4):296-302.
CASE REPORT
We report three cases of diffuse large B-cell lymphoma of the mandible and a review of the literature. All 3 of our patients had stage I AE disease and had complete remission for more than 2 years after 42-46 Gy of irradiation to the primary tumor with regional lymph nodes and 3 courses of chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, and predonisolone (CHOP). Literature analysis, although biased toward published data, indicated that the 3-year disease-specific survival rates for non-Hodgkin's lymphoma (NHL) of the mandible were 90.5% and 47.6% for stages I and II, respectively. The treatment results for NHL of the mandible may be similar to general primary bone NHL and to other extranodal NHL's.
CONCLUSION
Radiotherapy alone is not sufficient for tumor control for stage I+II, disease, and combination chemotherapy may be needed.
病例报告
我们报告了3例下颌骨弥漫性大B细胞淋巴瘤病例并对文献进行了综述。我们的所有3例患者均为ⅠAE期疾病，对原发肿瘤及区域淋巴结进行42 - 46 Gy照射，并接受由环磷酰胺、阿霉素、长春新碱和泼尼松龙组成的3个疗程化疗（CHOP方案）后，均获得了超过2年的完全缓解。文献分析虽然偏向于已发表的数据，但表明下颌骨非霍奇金淋巴瘤（NHL）Ⅰ期和Ⅱ期的3年疾病特异性生存率分别为90.5%和47.6%。下颌骨NHL的治疗结果可能与一般原发性骨NHL及其他结外NHL相似。
结论
对于Ⅰ + Ⅱ期疾病，单纯放疗不足以控制肿瘤，可能需要联合化疗。
Zotero 插件